Gradalis plans to conduct a Phase II trial that is intended to support an accelerated approval application for Vigil. Image Credit: Nemes Laszlo / Shutterstock.

Gradalis has received a $9.9m product development research grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the Phase II ovarian cancer study of the company’s lead candidate, Vigil (gemogenovatucel-T).

The planned Phase II trial will evaluate Vigil in patients with recurrent ovarian cancer with homologous recombination proficient (HRP) molecular profiles who are sensitive to platinum therapies. The trial is intended to confirm positive Phase II VITAL trial results and support an accelerated approval application, as per a 16 November press release.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

US-based immunotherapy company Gradalis intends to fill the unmet needs of the specific patient group left by the market withdrawal of poly (ADP-ribose) polymerase (PARP) inhibitors. In 2022, the pharmaceutical companies withdrew three PARP inhibitors, namely Clovis Oncology’s Rubraca (rucaparib), AstraZeneca/Merck & Co (MSD)’s Lynparza (olaparib), and GSK’s Zejula (niraparib), indicated for heavily pre-treated advanced ovarian cancer, after long-term studies showed low efficacy, or even a detrimental effect in one case, compared to chemotherapy.

The cell therapy market for ovarian cancer in the eight major markets is forecasted to be worth $9.8bn in 2031, as per a GlobalData report. The autologous gene-modified cell therapies (GMCTs) and gene therapies are estimated to generate $645m and $433m in peak sales, respectively.

GlobalData is the parent company of Pharmaceutical Technology.

See Also:

Vigil is a bifunctional short hairpin RNA (bi-shRNA) immunotherapy that modifies tumour cells to reduce furin enzyme levels, thereby facilitating an immune response to cancer cells. The drug is designed to elicit a targeted and personalised immune response to a patient’s unique “clonal” tumour neoantigens.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised placebo-controlled Phase II VITAL study (NCT02346747) enrolled patients with stage IIIb-IV ovarian cancer. Vigil-treated patients demonstrated improved recurrence free survival (RFS) compared to placebo, as per a 26 March press release. Furthermore, no Grade III/IV treatment-related toxicities were seen in the study.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. 

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.